Royal Bank of Canada
SIOX

Royal Bank of Canada’s Sio Gene Therapies Inc. Common Stock SIOX Stock Holding History

Royal Bank of Canada’s Portfolio SIOX Stock Details SIOX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-12,500
Closed -$27K – 8078
2021
Q3 		$27K Hold
12,500
– – ﹤0.01% 6529
2021
Q2 		$34K Hold
12,500
– – ﹤0.01% 6286
2021
Q1 		$33K Sell
12,500
-1,500
-11% -$4.24K ﹤0.01% 6148
2020
Q4 		$39K Sell
14,000
-732
-5% -$2.13K ﹤0.01% 5765
2020
Q3 		$68K Buy
14,732
+732
+5% +$2.42K ﹤0.01% 5206
2020
Q2 		$39K Sell
14,000
-498
-3% -$1.6K ﹤0.01% 5336
2020
Q1 		$36K Sell
14,498
-100
-0.7% -$361 ﹤0.01% 5314
2019
Q4 		$75K Buy
14,598
+1,870
+15% +$10.4K ﹤0.01% 5239
2019
Q3 		$82K Buy
12,728
+72
+0.6% +$496 ﹤0.01% 4901
2019
Q2 		$79K Sell
12,656
-313
-2% -$2.38K ﹤0.01% 5011
2019
Q1 		$138K Buy
12,969
+469
+4% +$4.67K ﹤0.01% 4573
2018
Q4 		$100K Buy
12,500
+12,112
+3,122% +$175K ﹤0.01% 4722
2018
Q3 		$7K Sell
388
-340
-47% -$6.19K ﹤0.01% 6139
2018
Q2 		$13K Buy
728
+347
+91% +$5.12K ﹤0.01% 5743
2018
Q1 		$4K Buy
381
+6
+2% +$96 ﹤0.01% 6009
2017
Q4 		$16K Sell
375
-812
-68% -$36.4K ﹤0.01% 5698
2017
Q3 		$65K Sell
1,187
-91
-7% -$15.4K ﹤0.01% 5275
2017
Q2 		$237K Sell
1,278
-828
-39% -$145K ﹤0.01% 4255
2017
Q1 		$252K Sell
2,106
-589
-22% -$61.7K ﹤0.01% 4188
2016
Q4 		$268K Buy
2,695
+107
+4% +$11.3K ﹤0.01% 4288
2016
Q3 		$290K Buy
2,588
+1,275
+97% +$153K ﹤0.01% 4165
2016
Q2 		$135K Buy
1,313
+1,082
+468% +$108K ﹤0.01% 4645
2016
Q1 		$21K Sell
231
-1,991
-90% -$212K ﹤0.01% 5473
2015
Q4 		$321K Buy
2,222
+74
+3% +$9.63K ﹤0.01% 4180
2015
Q3 		$222K Buy
2,148
+2,085
+3,310% +$244K ﹤0.01% 4235
2015
Q2 		$10K Buy
+63
New +$10.7K ﹤0.01% 6057

Other funds holding SIOX

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PFM
Privium Fund Management Amsterdam, Netherlands $544M AUM 72.49% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
CIA
Cladis Investment Advisory Billings, Montana $182M AUM 33.3% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Royal Bank of Canada's SIOX Position: Q4 2021 in Review

Royal Bank of Canada sold out of Sio Gene Therapies Inc. Common Stock (SIOX) in Q4 2021, closing a stake of 12,500 shares — an estimated $27K sold.

Royal Bank of Canada first reported a position in SIOX in Q2 2015 and held it in 26 quarters. The position peaked at $321K in Q4 2015. 48 funds tracked by Wall St. Rank hold SIOX as of Q4 2021.

  • Royal Bank of Canada reported no remaining Sio Gene Therapies Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
  • Royal Bank of Canada sold 12,500 Sio Gene Therapies Inc. Common Stock shares in Q4 2021, an estimated $27K.
  • Royal Bank of Canada first reported a position in Sio Gene Therapies Inc. Common Stock in Q2 2015 and held it in 26 quarters.
  • Royal Bank of Canada's Sio Gene Therapies Inc. Common Stock position peaked at $321K in Q4 2015.
  • 48 funds tracked by Wall St. Rank held Sio Gene Therapies Inc. Common Stock as of Q4 2021.

Based on Royal Bank of Canada's 13F filing for Q4 2021, filed 14 Feb 2022.